|
|
Post by larrysc on Mar 10, 2015 23:50:14 GMT
|
|
|
|
Post by georger on Oct 5, 2015 1:48:20 GMT
Here's something to keep an eye on. This is an extract from a conference agenda in the US in August 2015:
Johann Bohm (Institute of Genetics and Molecular and Cellular Biology, France)
"Mutations in the SOCE Genes STIM1, ORAI1 and CASQ1 Cause Tubular Aggregate Myopathy (TAM)"
This is all I can find about this 3rd gene CASQ1 and TAM. They haven't published anything yet. CASQ1 has previously been associated with an aggregate myopathy but not TAM.
|
|
|
|
Post by georger on Nov 18, 2015 3:51:47 GMT
Continuing the theme of research into rare diseases, see this: www.bbc.co.uk/programmes/b06mdbnqThis is a BBC interview with the head of R & D at GlaxoSmithKline. It has nothing specifically to do with TAM, but at about 12 minutes and 40 seconds they talk about the company's rare diseases unit and the rationale for it. I always thought that increased research on TAM would only happen if someone rich, powerful and important got the disease. Well, along came the DNA research at IGBMC and other places and here is the reason why a mega pharmaceutical company researches rare diseases. |
|
|
|
Post by Craig Lane on Nov 19, 2015 19:22:53 GMT
Interesting rationale and hopefully it will produce results. Maybe not in time to benefit us but the very fact that someone somewhere is looking gives hope.
I was of the same opinion that until someone rich or influential was affected no research would happen. Seem the interest in DNA cause and affect research may throw some light in our direction.
|
|
